Mechoulam’s latest research on a new family of cannabinoid acid molecules will be exposed today and tomorrow at CannaMed 2019
Raphael Mechoulam, father of cannabis research, is the speaker with the most excitement in this edition of CannaMed 2019. This Israeli scientist who managed to synthesize THC for the first time, and current director of EPM research, will speak today and tomorrow at CannaMed on the science and chemistry behind its latest innovation, a new family of stable cannabinoid acid molecules whose potency is superior to that of existing cannabinoids, and which also have very promising therapeutic properties.
Indeed, Medicinal Genomics Corp. (MGC), a leader company in blockchain genetics and technology to improve the performance and safety of cannabis sponsored by CannaMed, has announced to the media that today and tomorrow (September 23 and 24) Raphael Mechoulam will head the list of more than 50 speakers and presenters at CannMed 2019, which this year takes place at the Pasadena Convention Center, Pasadena, California.
This edition of CannaMed is sponsored by Medicinal Genomics in association with EPM. Raphael Mechoulam is the research director of EPM, a US-based company. UU. and leader in the study of stable cannabinoid acid molecules, topic of Raphael Mechoulam’s latest research . EPM aims to close the gap between pharmaceutical industries and cannabis industries by developing a platform for cannabis-based drug creators to access their technology of stable acid molecules in an effort to advance science and Support the development of new medical treatments.
During this edition of CannaMed, Raphael Mechoulam will talk about his Acid program, which he directs at EPM. The Mechoulam conference will include new data, never before presented in a scientific forum, and finally EPM will present its stable acid technology for the first time.
Since Professor Mechoulam discovered the human endocannabinoid system in the 1960s, and his subsequent work done for almost six decades identifying cannabis phytocannabinoids, this internationally renowned scientist has been recognized as the “father of cannabis research.” In addition to the opening speech and announcement of Mechoulam, this fourth annual CannMed 2019 conference will feature the participation of medical cannabis industry professionals, doctors and cannabis advocates from around the world who have joined in this event to share the latest advances in medical cannabis.
Raphael Mechoulam was born in Bulgaria in 1930 and he went to Israel with his family in 1949, where he studied chemistry. Mechoulam earned his doctorate in physics from the Weizmann Institute in 1958, with a thesis on steroid chemistry. After conducting postdoctoral studies at the Rockefeller Institute in New York (1959–60), he became a member of the Weizmann Institute (1960–65) scientific team, where he specialized in the isolation and total synthesis of the main active principles of cannabis Subsequently, Raphael Mechoulam began working at the Hebrew University of Jerusalem, in the Department of Medicinal Chemistry since 1975, where he established the “Department of Natural Products”. His main scientific interest is the chemistry and pharmacology of cannabinoids. In 1994 he was elected member of the Academy of Sciences and Humanities of Israel. The recognized as ‘father of marijuana’ first isolated THC, the plant’s main psychoactive ingredient, in the 1960s.
